Roche Pharma launches drug to treat breast cancer

The company has launched PHESGO the first ever fixed dose formulation in oncology to combine two monoclonal antibodies – Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic breast cancer.